To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Exclusion Criteria

• •Subject who has history of any diseases following. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)
• •History of bleeding disorder
• •Infection, dermatological condition or scar at the treatment injection sites
• •Subject who has marked facial asymmetry
• •History of facial nerve palsy or eyebrow/eyelid ptosis
• •History of surgical procedures affecting on the lines of forehead and/or middle of the forehead areas
• •History of malignant tumor within 5 years (except for basal cell carcinoma
• •Any disease and condition that, in the view of the investigator, would interfere with study participation
• •History of alcohol or drug addiction
• •Subject who has been treated with any botulinum toxin drug within 6 months
• •Persons who have received the following drugs with systemic muscle relaxant action within 4 weeks of screening
• •Subjects taking more than 1,000 IU/day of anticoagulants, antiplatelet agents, NSAIDs, or vitamin E within 7 days prior to administration of the investigational drug (excluding low-dose aspirin)
• •A person who has received a retinoid series of medications during the following period as of the time of screening
• •Subjects who have hypersensitivity reaction to investigational drug or local anesthetics
• •History of Anaphylaxis or severe combined allergy disease
• •Subject who has physically untreatable glabellar lines like that can't be spread out even if someone forces it to spread out
• •Pregnant and lactating women F- ertile women and men who have plans to pregnancy and who do not agree to appropriate contraception.
• •Participant who has been treated with any investigational drug within 30 days from screening